Editors Pride

The Alzheimer’s Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Alzheimer’s Disease Pipeline Insight, 2026“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Alzheimer’s Disease Market.

Some of the key takeaways from the Alzheimer’s Disease Pipeline Report:

• Companies across the globe are diligently working toward developing novel Alzheimer’s Disease treatment therapies with a considerable amount of success over the years.

• Alzheimer’s Disease companies working in the treatment market are Alpha Cognition, Biogen/Eisai, Eli Lilly, Otsuka Pharma/ Lundbeck, Suven Life Sciences, Roche, Annovis Bio, and others, are developing therapies for the Alzheimer’s Disease treatment

• Emerging Alzheimer’s Disease therapies in the different phases of clinical trials are- ZUNVEYL (benzgalantamine), LEQEMBI (lecanemab), KISUNLA (donanemab-azbt), REXULTI (brexpiprazole), Masupirdine (SUVN-502), Trontinemab (RG6102), Buntanetap (ANVS401), and others are expected to have a significant impact on the Alzheimer’s Disease market in the coming years.

• In October 2026, Banner Alzheimer’s Institute and its research partners announced that the first participant had been randomized in a prevention trial involving individuals with a genetic mutation linked to autosomal dominant Alzheimer’s disease. The study is assessing donanemab, an approved anti-amyloid therapy, followed by comparisons of treatment approaches using donanemab, investigational nivagacetor, or a combination of both. The research aims to determine whether Alzheimer’s disease onset can be delayed or prevented in individuals at exceptionally high genetic risk.

• In September 2026, NewAmsterdam Pharma announced the dosing of the first participant in the Phase IIb SPINOZA trial, which is evaluating obicetrapib in individuals with biomarker-confirmed preclinical Alzheimer’s disease. The study will examine changes in Alzheimer’s-related biomarkers, including plasma phosphorylated tau 217 (p-tau217), as well as assess cognitive performance and functional outcomes.

• In September 2026, Acadia Pharmaceuticals announced topline findings from the Phase II segment of the RADIANT program investigating remlifanserin for hallucinations and delusions associated with Alzheimer’s disease psychosis. Although the study narrowly failed to meet its primary endpoint, it demonstrated a nominally significant improvement in a key secondary endpoint. The company plans to proceed with its two ongoing Phase III trials, underscoring the continued need for additional treatment options for psychosis associated with Alzheimer’s disease.

• In August 2026, The US FDA approved TAUKLARIFY (florquinitau F 18 injection), developed by Lantheus, as a radiodiagnostic agent for brain PET imaging in adults with cognitive impairment undergoing evaluation for Alzheimer’s disease. The agent enables visualization of tau neurofibrillary tangles, supporting diagnostic assessment of the disease rather than serving as a therapeutic treatment.

• In July 2026, The US FDA approved a supplemental application for LEQEMBI IQLIK (lecanemab-irmb), an autoinjector-delivered subcutaneous formulation, for initiating treatment in patients with early Alzheimer’s disease. This approval provides an alternative to intravenous treatment initiation and may enhance convenience for eligible patients with mild cognitive impairment or mild dementia associated with Alzheimer’s disease.

• In April 2026, The US FDA approved an expanded indication for Auvelity (dextromethorphan hydrobromide and bupropion hydrochloride) for the treatment of agitation associated with Alzheimer’s disease dementia in adults. This approval marks the first FDA-authorized non-antipsychotic therapy for this indication and was supported by two randomized clinical trials that demonstrated improvements in agitation-related outcomes.

• In February 2026, Eisai Limited and Biogen Canada Inc. expressed disappointment and disagreement with the decision by the Canada’s Drug Agency (CDA-AMC) not to recommend LEQEMBI® for public reimbursement in Canada. The companies emphasized that this draft decision comes despite clinical evidence demonstrating that LEQEMBI® can help slow disease progression and functional decline in patients with early Alzheimer’s Disease.

• In December 2025, Spinogenix’s lead asset, tazbentetol, demonstrated early, sustained cognitive improvements in individuals with mild-to-moderate Alzheimer’s disease in a mid-stage clinical study. In the Phase IIa trial (NCT06427668), the once-daily oral small molecule produced early cognitive gains, with patients on the 300 mg high dose showing an average improvement of more than 2.5 points in SMMSE scores compared with placebo within just four weeks. These benefits persisted in participants who continued into the 24-week open-label extension. Comparable positive effects were also observed across other primary endpoints, including CDR-SB and activities of daily living (ADL) assessments.

• In November 2025, Biogen Inc. (Nasdaq: BIIB) announced that it will present new scientific data at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference, scheduled for December 1-4 in San Diego. Presentations on LEQEMBI® (lecanemab-irmb) will cover results on subcutaneous initiation dosing, advantages of ongoing treatment, and projected long-term time savings over a decade based on Phase 3 data, along with real-world findings from a post-marketing study in Japan and the ALZ-NET registry. The company will also unveil updated information on BIIB080, an investigational antisense oligonucleotide, drawn from a healthy-volunteer biodistribution study, plus research enhancing understanding of disease progression.

• In June 2025, The UAB Brain Aging and Memory Clinic, which opened in spring 2024, ushers in a new chapter of care for Alzheimer’s disease and memory disorders in Alabama and the surrounding region. This facility has played a key role in supporting clinical trials, strengthening UAB’s position as a leading site for testing the latest generation of anti-Alzheimer therapies.

• In July 2025, INmune Bio’s stock dropped over 50% after its TNF inhibitor failed to show efficacy in Alzheimer’s patients in a Phase II trial. The MINDFuL study (NCT05318976) tested XPro (pegipanermin), a selective soluble TNF inhibitor, in early Alzheimer’s patients with inflammatory biomarkers. While no overall benefit was observed at the six-month mark in the intent-to-treat group, patients with two or more inflammation biomarkers showed a modest 0.27-point improvement on the Early Mild Alzheimer’s Cognitive Composite (EMACC) and a -0.20 change in pTau217 blood levels. INmune Bio suggests this subgroup might benefit from XPro.

• In April 2025, Biogen Inc. (Nasdaq: BIIB) announced that the U.S. Food and Drug Administration (FDA) has awarded Fast Track designation to BIIB080, an experimental antisense oligonucleotide (ASO) therapy targeting tau, for treating Alzheimer’s disease. This designation aims to accelerate the development and review process of investigational drugs addressing serious diseases with unmet medical needs.

• In March 2025, Acumen Pharmaceuticals completed enrollment for its multi-center, double-blind Phase II ALTITUDE-AD trial evaluating the humanized monoclonal antibody sabirnetug (ACU193) in patients with early Alzheimer’s disease. Sabirnetug is noted as the first antibody to selectively target amyloid beta oligomers (AβOs), a toxic form of amyloid beta implicated in the early stages of Alzheimer’s. The ALTITUDE-AD trial, initiated last year, is a randomized, placebo-controlled study that has enrolled 542 participants across Canada, the EU, the US, and the UK.

• In February 2025, AUS University has initiated a prevention trial to study Eli Lilly’s investigational drug remternetug in young adults, aiming to halt the progression of Alzheimer’s disease. Meanwhile, Washington University School of Medicine has announced the enrollment of the first participants in its Alzheimer’s disease DIAN-TU-002 primary prevention trial (NCT06647498). This study plans to recruit 240 individuals from families carrying mutations in one of three key genes linked to Alzheimer’s, who have a family history placing them at risk of developing the disease in their 30s, with some participants as young as 18 years old.

Alzheimer’s Disease Overview

Alzheimer’s Disease is a progressive neurodegenerative disorder that primarily affects memory, thinking, and behavior. It is the most common cause of dementia in older adults. Alzheimer’s occurs when abnormal protein deposits (like beta-amyloid plaques and tau tangles) build up in the brain, leading to the loss of nerve cells and brain shrinkage.

Early symptoms include forgetfulness, confusion, and difficulty with everyday tasks. As the disease advances, it leads to severe memory loss, personality changes, and dependence on others for care. Currently, there is no cure, but treatments aim to slow progression and improve quality of life.

Get a Free Sample PDF Report to know more about Alzheimer’s Disease Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/alzheimers-disease-ad-pipeline-insight

Emerging Alzheimer’s Disease Drugs Under Different Phases of Clinical Development Include:

• ZUNVEYL (benzgalantamine): Alpha Cognition

• LEQEMBI (lecanemab): Biogen/Eisai

• KISUNLA (donanemab-azbt): Eli Lilly

• REXULTI (brexpiprazole): Otsuka Pharma/ Lundbeck

• Masupirdine (SUVN-502): Suven Life Sciences

• Trontinemab (RG6102): Roche

• Buntanetap (ANVS401): Annovis Bio

Alzheimer’s Disease Route of Administration

Alzheimer’s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Intravenous

• Subcutaneous

• Oral

• Intramuscular

Alzheimer’s Disease Molecule Type

Alzheimer’s Disease Products have been categorized under various Molecule types, such as

• Monoclonal antibody

• Small molecule

• Peptide

Alzheimer’s Disease Pipeline Therapeutics Assessment

• Alzheimer’s Disease Assessment by Product Type

• Alzheimer’s Disease By Stage and Product Type

• Alzheimer’s Disease Assessment by Route of Administration

• Alzheimer’s Disease By Stage and Route of Administration

• Alzheimer’s Disease Assessment by Molecule Type

• Alzheimer’s Disease by Stage and Molecule Type

DelveInsight’s Alzheimer’s Disease Report covers around 220+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Alzheimer’s Disease product details are provided in the report. Download the Alzheimer’s Disease pipeline report to learn more about the emerging Alzheimer’s Disease therapies

Some of the key companies in the Alzheimer’s Disease Therapeutics Market include:

Key companies developing therapies for Alzheimer’s Disease are – AbbVie, Inc., Teva Pharmaceuticals Ltd., Eisai Co., Ltd., Janssen Pharmaceuticals, Inc., Johnson & Johnson, Novartis AG, Zydus Lifesciences Ltd (CADILA), Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd, Aurobindo Pharma Ltd, Amneal Pharmaceuticals Inc., Macleods Pharmaceuticals Ltd., Viatris Inc., Lupin Ltd, Cipla Ltd., Torrent Pharmaceuticals Ltd., Unichem laboratories ltd, Lannett Inc., and others.

Alzheimer’s Disease Pipeline Analysis:

The Alzheimer’s Disease pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Alzheimer’s Disease with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Alzheimer’s Disease Treatment.

• Alzheimer’s Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Alzheimer’s Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Alzheimer’s Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Alzheimer’s Disease drugs and therapies

Alzheimer’s Disease Pipeline Market Drivers

• Rising Disease Prevalence: The growing global burden of Alzheimer’s disease, particularly among aging populations, is increasing the demand for innovative therapies and accelerating pipeline development.

• Advancements in Disease-Modifying Therapies: Progress in amyloid-beta-targeting treatments, tau-based therapies, and other disease-modifying approaches is expanding the Alzheimer’s disease drug pipeline.

• Increasing R&D Investments: Rising investments from pharmaceutical and biotechnology companies are supporting the discovery and development of novel drug candidates.

• Growing Clinical Trial Activity: An increase in clinical trials investigating new mechanisms of action, combination therapies, and early-stage interventions is strengthening the treatment pipeline.

• Unmet Medical Needs: Limited treatment options capable of substantially slowing disease progression are encouraging research into more effective and personalized therapeutic approaches.

Alzheimer’s Disease Pipeline Market Barriers

• High Clinical Trial Failure Rates: The complex biology of Alzheimer’s disease and difficulties demonstrating meaningful clinical benefits contribute to high failure rates in drug development.

• Challenges in Early Diagnosis: Difficulty identifying the disease during its earliest stages can delay patient enrollment in clinical trials and complicate the evaluation of emerging therapies.

• High R&D Costs: The lengthy development timelines, large clinical trials, and substantial research investments required for Alzheimer’s therapies create financial challenges for developers.

• Safety and Tolerability Concerns: Potential adverse effects, including amyloid-related imaging abnormalities (ARIA) associated with certain anti-amyloid therapies, may complicate clinical development and treatment adoption.

• Uncertain Regulatory and Commercial Outcomes: Demonstrating clinically meaningful benefits, securing regulatory approval, and establishing cost-effectiveness can create barriers to the successful commercialization of pipeline therapies.

Scope of Alzheimer’s Disease Pipeline Drug Insight

• Coverage: Global

• Key Alzheimer’s Disease Companies: Alpha Cognition, Biogen/Eisai, Eli Lilly, Otsuka Pharma/ Lundbeck, Suven Life Sciences, Roche, Annovis Bio, and others

• Key Alzheimer’s Disease Therapies: ZUNVEYL (benzgalantamine), LEQEMBI (lecanemab), KISUNLA (donanemab-azbt), REXULTI (brexpiprazole), Masupirdine (SUVN-502), Trontinemab (RG6102), Buntanetap (ANVS401), and others

• Alzheimer’s Disease Therapeutic Assessment: Alzheimer’s Disease current marketed and Alzheimer’s Disease emerging therapies

• Alzheimer’s Disease Market Dynamics: Alzheimer’s Disease market drivers and Alzheimer’s Disease market barriers

Request for Sample PDF Report for Alzheimer’s Disease Pipeline Assessment and clinical trials

Table of Contents

1. Alzheimer’s Disease Report Introduction

2. Alzheimer’s Disease Executive Summary

3. Alzheimer’s Disease Overview

4. Alzheimer’s Disease- Analytical Perspective In-depth Commercial Assessment

5. Alzheimer’s Disease Pipeline Therapeutics

6. Alzheimer’s Disease Late Stage Products (Phase II/III)

7. Alzheimer’s Disease Mid Stage Products (Phase II)

8. Alzheimer’s Disease Early Stage Products (Phase I)

9. Alzheimer’s Disease Preclinical Stage Products

10. Alzheimer’s Disease Therapeutics Assessment

11. Alzheimer’s Disease Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Alzheimer’s Disease Key Companies

14. Alzheimer’s Disease Key Products

15. Alzheimer’s Disease Unmet Needs

16 . Alzheimer’s Disease Market Drivers and Barriers

17. Alzheimer’s Disease Future Perspectives and Conclusion

18. Alzheimer’s Disease Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services